ClinicalTrials.gg
CompletedNCT05856760SPARTACUSUpdated Nov 20, 2025Results posted

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

A Phase 2 interventional study of Sparsentan in Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics, Inc.. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Travere Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
40th of 67
48 · median 67
Started
2023
with 5 others
Phase 2
30 of 73
11 open now
Registered
44th of 73
by date
Lead sponsor
4 of 73
Travere Therapeutics, Inc.

Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 40th largest by enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2023, is one of 30 in phase 2, and was the 44th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry

Read the detailed description

This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with Immunoglobulin A Nephropathy (IgAN) who are at risk of disease progression to kidney failure (KF) despite being on both stable renin angiotensin aldosterone system inhibitor (RAASi) and sodium glucose cotransporter-2 (SGLT2) inhibitor treatment for at least 12 weeks prior to study entry.

Participants who provided written informed consent were assessed for eligibility and underwent baseline evaluations including clinical laboratory tests. Per the eligibility criteria, all participants were required to be on a stable dose(s) of angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) and on a stable dose of a SGLT2 inhibitor at screening and continued their stable treatments through the screening period. Eligible participants discontinued ACEI and/or ARB therapy the day before the Day 1 visit and remained on stable SGLT2 inhibitor dosing for the duration of the study.

Study intervention was administered daily for a treatment period of 24 weeks with study visits conducted at weeks 2-, 4-, 12-, and 24- following Day 1. Following the 24-week treatment period, study intervention was discontinued for 4 weeks and standard of care RAASi treatment resumed, with a safety visit at Week 28.

03

Conditions studied

  • Immunoglobulin A Nephropathy

Keywords

  • IgAN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years at the time of signing the .
  • -proven IgAN. The biopsy may have been performed at any time in the past.
  • UA/C ≥0.3 g/g at screening
  • An value of ≥25 mL/min/1.73m\^2 at screening.
  • On a stable dose of an SGLT2 inhibitor for at least 12 weeks prior to screening.
  • On a stable dose of ACEI and/or ARB therapy for at least 12 weeks prior to screening that is:

    • The participant's maximum tolerated dose (MTD), and
    • at least one half of the maximum labeled dose (MLD)
  • Systolic BP must be ≤160 mmHg, and diastolic BP must be ≤110 mmHg at screening.
  • For participants receiving chronic low dose systemic (defined as ≤10 mg/day prednisone or equivalent), or an enteric formulation of budesonide and/or a mineralocorticoid receptor antagonist (MRA), the dosage must be stable for ≥12 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • IgAN secondary to another condition or immunoglobulin A (IgA) vasculitis.
  • Undergone any organ transplant, with the exception of corneal transplants.
  • Documented history of heart failure.
  • Taking high dose (defined as >10 mg/day prednisone) or other any systemic medications within 12 weeks of prior to screening.
  • Has cerebrovascular disease ( or stroke) and/or coronary artery disease (hospitalization for myocardial infarction unstable angina, new onset of angina with positive functional tests, coronary angiogram revealing stenosis, or a coronary revascularization procedure) within 3 months prior to screening.
  • Has jaundice, hepatitis, or known hepatobiliary disease (excluding asymptomatic cholelithiasis), or and/or AST >2 times the range at screening.
  • Has a history of other than adequately treated basal cell or squamous cell skin cancer or cervical carcinoma within the past 2 years.
  • Has a history of serious side effect or allergic response to any AngII antagonist, ERA or sparsentan, or has a to any of the in the study intervention.
  • Requires any of the prohibited concomitant medications.
  • Treatment with sparsentan within 12 weeks prior to screening
  • Has participated in a study of another product within 28 days prior to screening or plans to participate in such a study during the course of this study.
  • Has a screening hematocrit value \<27% (0.27 Volume/Volume) or value \<9 g/dL (90 g/L).
  • Has a screening potassium value of >5.5 mEq/L (5.5 mmol/L).
  • Is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.
  • The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study, including the ability to swallow the study intervention capsules whole.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    sparsentan

    Sparsentan will be administered daily as a 200-mg oral tablet. The goal is to titrate from the initial dose of 200 mg (Day 1) to the target dose of 400 mg at Week 2.

    Drug: Sparsentan

Interventions

  • Target dose of 400 mg daily

    Also known as: Filspari, RE-021

06

What researchers measure

Primary outcomes

  1. Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24

    The change from baseline in UA/C at Week 24 based on first morning void (FMV) samples

    Time frame: Week 24

Secondary outcomes

  1. UA/C <0.2 g/g at Week 24

    Achievement of UA/C of \<0.2 g/g at Week 24 based on FMV samples

    Time frame: Week 24

  2. 30% Reduction From Baseline in UA/C at Week 24

    Achievement of 30% reduction from baseline in UA/C at Week 24 based on FMV samples

    Time frame: Week 24

  3. 50% Reduction From Baseline in UA/C at Week 24

    Achievement of 50% reduction from baseline in UA/C at Week 24 based on FMV samples

    Time frame: Week 24

  4. Change in Urine Protein-to-creatinine Ratio (UP/C) at Week 24

    The change from baseline in UP/C at Week 24 based on FMV samples

    Time frame: Week 24

  5. Estimated Glomerular Filtration Rate (eGFR)

    Change from baseline estimated glomerular filtration rate at 24 weeks

    Time frame: Week 24

  6. Systolic Blood Pressure (BP) at Week 24

    The change from baseline in systolic BP at Week 24

    Time frame: Week 24

  7. Change in Diastolic Blood Pressure (BP)

    The change from baseline in diastolic BP at Week 24

    Time frame: Week 24

07

Results

Posted Nov 20, 2025

Participant flow

Forty-eight participants were enrolled in the study and all 48 (100%) received at least 1 dose of sparsentan. Sparsentan was prematurely discontinued in 9 participants (19%). Forty-one participants (85%) completed the study, and 7 participants (15%) discontinued the study. The most common reasons for discontinuation from the study were withdrawal by participant (3 participants \[6%\]) and AEs (2 participants \[4%\]).

Participant flow — Overall Study
MilestoneSparsentan
Started48
Discontinued7
Completed41
Not completed7
Withdrew: Adverse event2
Withdrew: Physician decision1
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryChange in Urine Albumin-creatinine Ratio (UA/C) at Week 24

The change from baseline in UA/C at Week 24 based on first morning void (FMV) samples

Time frame:
Week 24
Reported as:
Least squares mean · percent change
Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24
percent changeSparsentan
Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24-55.78 (-65.8 to -42.8)
SecondaryUA/C <0.2 g/g at Week 24

Achievement of UA/C of \<0.2 g/g at Week 24 based on FMV samples

Time frame:
Week 24
Reported as:
Number · percentage of participants
UA/C <0.2 g/g at Week 24
percentage of participantsSparsentan
UA/C <0.2 g/g at Week 2431 (17.0 to 47.6)
Secondary30% Reduction From Baseline in UA/C at Week 24

Achievement of 30% reduction from baseline in UA/C at Week 24 based on FMV samples

Time frame:
Week 24
Reported as:
Number · percentage of participants
30% Reduction From Baseline in UA/C at Week 24
percentage of participantsSparsentan
30% Reduction From Baseline in UA/C at Week 2477 (60.7 to 88.9)
Secondary50% Reduction From Baseline in UA/C at Week 24

Achievement of 50% reduction from baseline in UA/C at Week 24 based on FMV samples

Time frame:
Week 24
Reported as:
Number · percentage of participants
50% Reduction From Baseline in UA/C at Week 24
percentage of participantsSparsentan
50% Reduction From Baseline in UA/C at Week 2451 (34.8 to 67.6)
SecondaryChange in Urine Protein-to-creatinine Ratio (UP/C) at Week 24

The change from baseline in UP/C at Week 24 based on FMV samples

Time frame:
Week 24
Reported as:
Least squares mean · percentage change
Change in Urine Protein-to-creatinine Ratio (UP/C) at Week 24
percentage changeSparsentan
Change in Urine Protein-to-creatinine Ratio (UP/C) at Week 24-45.20 (-54.6 to -33.9)
SecondaryEstimated Glomerular Filtration Rate (eGFR)

Change from baseline estimated glomerular filtration rate at 24 weeks

Time frame:
Week 24
Reported as:
Geometric mean · mL/min/1.73 square meter
Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73 square meterSparsentan
Estimated Glomerular Filtration Rate (eGFR)-2.0 (-3.9 to -0.1)
SecondarySystolic Blood Pressure (BP) at Week 24

The change from baseline in systolic BP at Week 24

Time frame:
Week 24
Reported as:
Least squares mean · mmHg
Systolic Blood Pressure (BP) at Week 24
mmHgSparsentan
Systolic Blood Pressure (BP) at Week 24-3.4 (-6.8 to 0.0)
SecondaryChange in Diastolic Blood Pressure (BP)

The change from baseline in diastolic BP at Week 24

Time frame:
Week 24
Reported as:
Least squares mean · mmHg
Change in Diastolic Blood Pressure (BP)
mmHgSparsentan
Change in Diastolic Blood Pressure (BP)-4.6 (-6.7 to -2.4)

Adverse events

Collected over 525 Days (1 year, 5 months, and 6 days) Continuous monitoring from Day -42 (screening) to Week 28 (safety follow-up visit). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sparsentan0/48 (0%)4/48 (8.3%)26/48 (54.2%)
Most frequent serious events
Most frequent serious events
EventSparsentan
OsteoarthritisMusculoskeletal and connective tissue disorders1/48
Cerebrovascular eventNervous system disorders1/48
Acute kidney injuryRenal and urinary disorders1/48
Deep vein thrombosisVascular disorders1/48
Chemical burnInjury, poisoning and procedural complications1/48
Most frequent other events
Most frequent other events
EventSparsentan
HypotensionVascular disorders7/48
HeadacheNervous system disorders4/48
OedemaGeneral disorders4/48
Oedema peripheralGeneral disorders4/48
Upper respiratory tract infectionInfections and infestations4/48
DizzinessNervous system disorders3/48

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sparsentan
Median48 (19 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Sparsentan
Female20
Male28
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sparsentan
Race — White28
Race — Black or African American1
Race — Asian19
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sparsentan
Ethnicity — Hispanic or Latino5
Ethnicity — Not Hispanic or Latino42
Ethnicity — Not Reported1
Region of Enrollment
Region of Enrollment(participants)Sparsentan
Hong Kong11
United States37
Height
Height(centimeters)Sparsentan
Mean168.2 ± 11.16
Weight
Weight(Kilograms)Sparsentan
Mean85.9 ± 22.25
BMI
BMI(kg/m^2)Sparsentan
Mean30.02 ± 5.619

3 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Travere Investigational Site
    Birmingham, Alabama 35233, United States
  • Travere Investigational Site
    Chula Vista, California 91910, United States
  • Travere Investigational Site
    Garden Grove, California 92844, United States
  • Travere Investigational Site
    Glendale, California 91206, United States
  • Travere Investigational Site
    Denver, Colorado 80230, United States
  • Travere Investigational Site
    Boise, Idaho 83706, United States
  • Travere Investigational Site
    Chubbuck, Idaho 83202, United States
  • Travere Investigational Site
    Idaho Falls, Idaho 83404, United States
  • Travere Investigational Site
    Chicago, Illinois 60611, United States
  • Travere Investigational Site
    Evergreen Park, Illinois 60805, United States
  • Travere Investigational Site
    Fort Wayne, Indiana 46804, United States
  • Travere Investigational Site
    Kansas City, Kansas 66160, United States
  • Travere Investigational Site
    Louisville, Kentucky 40205, United States
  • Travere Investigational Site
    Shreveport, Louisiana 71101, United States
  • Travere Investigational Site
    Albuquerque, New Mexico 87109, United States
  • Travere Investigation Site
    Clifton Park, New York 12065, United States
  • Travere Investigational Site
    Fresh Meadows, New York 11365, United States
  • Travere Investigational Site
    New York, New York 10013, United States
  • Travere Investigational Site
    Jacksonville, North Carolina 28546, United States
  • Travere Investigational Site
    New Bern, North Carolina 28562, United States
  • Travere Investigational Site
    Columbus, Ohio 43210, United States
  • Travere Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Travere Investigational Site
    Columbia, South Carolina 29203, United States
  • Travere Investigational Site
    Dallas, Texas 75230, United States
  • Travere Investigational Site
    Dallas, Texas 75246, United States
  • Travere Investigational Site
    Hong Kong, Hong Kong
  • Travere Investigational Site
    Kowloon, Hong Kong
  • Travere Investigational Site
    Shatin, Hong Kong
  • Travere Investigational Site
    Sheung Wan, Hong Kong
  • Travere Investigational Site
    Tsuen Wan, Hong Kong
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.

Time frame: Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication

Access criteria: Requires submission and approval of intended use and a data sharing agreement.

Data sharing details ↗ · travere.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Oct 2024, 16 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2023
First posted
May 12, 2023
StartActual
May 19, 2023
Primary completionActual
Oct 14, 2024
CompletionActual
Oct 25, 2024
Results first posted
Nov 20, 2025
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05856760
Lead sponsor
Travere Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 12, 2023
Start date
May 19, 2023
Primary completion
Oct 14, 2024
Completion
Oct 25, 2024
Results posted
Nov 20, 2025
Last update
Nov 20, 2025

Study contacts

Radko Komers, MD, PhD
study director · Travere Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sparsentan

Start the discussion